Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· June 8, 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight

View original at globenewswire.com

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight New York, USA, June 08, 2026 (GLOBE NEWSWIRE) -- Alcohol Use Disorder Market Set to Expand at a 12.1% CAG…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

The AUD market size was USD 1.1 billion across the 7MM in 2025
60% confidence
Altimmune expects to announce topline results from the RECLAIM Phase II trial evaluating pemvidutide in AUD in 2026
60% confidence
The United States accounted for the largest alcohol use disorder treatment market size in 2025 compared to EU4, UK, and Japan
60% confidence
The 12-month diagnosed prevalence of AUD in the US declined from approximately 10.6% in 2021 to approximately 9.7% in 2025
60% confidence
Brenipatide represents Eli Lilly's expansion into indications beyond obesity, including alcohol use disorder, opioid dependence, and asthma
60% confidence
Growing awareness, early AUD diagnosis, rising focus on harm reduction and personalized care, and strong clinical trial activity are expected to drive significant AUD market growth
60% confidence
Although several AUD therapies have been approved, treatment uptake remains substantially low, leaving a significant proportion of affected individuals untreated
60% confidence
The AUD market is projected to expand at a 12.1% CAGR during the forecast period 2026–2036
60% confidence
The AD04 patent, once granted, is expected to protect Adial's core assets through at least 2045
60% confidence
The exploration of novel mechanisms in AUD treatment such as 5-HT3 antagonism, NOP receptor modulation, mGluR5 NAM activity, and dual GLP-1/glucagon receptor agonism highlights significant opportunities for other developers to enter a space with high unmet need and to differentiate their pipelines through innovative, non-traditional targets
60% confidence
There were 25.6 million 12-months diagnosed prevalent cases of AUD in the US in 2025, which are projected to decrease by 2036
60% confidence
VIVITROL (naltrexone) holds the highest US AUD market share in 2025, while by 2036, AD04 is projected to capture the largest market
60% confidence